查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1972086

人工器官市场：依器官类型、产品类型、技术、最终用户和通路划分－2026-2032年全球预测

Artificial Organs Market by Organ Type, Product Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年人造器官市场价值为329.5亿美元，预计到2026年将成长至358.4亿美元，复合年增长率为9.26%，到2032年将达到612.8亿美元。

主要市场统计数据
基准年 2025 329.5亿美元
预计年份：2026年 358.4亿美元
预测年份 2032 612.8亿美元
复合年增长率 (%) 9.26%

全面概述生物技术和先进设备平台如何融合，从而改变器官衰竭的治疗选择和临床路径。

人工器官的研发和实用化体现了生物学、工程学和临床实践的融合，重塑了末期器官衰竭的治疗模式。材料科学、细胞生物学和製造技术在诊断、临时支持系统和长期植入式方案等领域的进步，正在拓展治疗选择，并催生新的医疗模式。临床医生越来越能够依赖结合机械支持和生物组件的混合疗法，从而稳定患者病情，弥补移植前的过渡期，或在移植不可行时提供根治性治疗。

技术整合、监管调整和策略伙伴关係是重组人工器官开发产品开发路径、临床护理模式和商业化策略的机制。

人工器官领域正经历一场变革，这场变革由三大相互关联的趋势所驱动：技术融合、临床路径重塑和供应链韧性。 3D生物列印、支架工程和微流体建模技术的进步，正推动着十年前还只是概念性的原型走向临床检验。因此，某些类型的人工器官产品开发週期正在缩短，而结合机械支撑和生物功能的混合解决方案也正从临床前研究走向早期临床应用。

本研究评估了 2025 年美国关税政策变更对人工器官製造商供应链筹资策略的影响，以及他们将製造地迁回美国的决策。

美国关税政策的近期变化对人工器官产业的製造商和经销商的供应链、零件采购和定价策略产生了重大影响。关税调整会影响用于设备製造的进口原材料和专用零件，例如聚合物、精密泵浦、感测器和生物製药加工设备，进而影响製造商的投入成本结构和采购计画。由于现代人工器官系统结构复杂，即使原料和子组件成本略有上涨，也会对材料清单(BOM) 计算和与医疗系统供应商的合约定价产生连锁反应。

一个详细的细分框架，将器官适应症、产品原型、技术平台、最终用户和通路联繫起来，以指导开发和商业投资的优先顺序。

细分市场分析提供了一个实用的观点，帮助我们理解患者需求、技术选择和医疗环境如何相互作用，进而影响产品开发和商业策略。按器官类型划分，我们检视了心臟、肾臟、肝臟、肺臟和胰臟的市场，每种器官路径都会产生独特的临床终点、设备需求和监管考量，这些都会影响临床试验设计和市场扩散曲线。按产品类型划分，我们检视了生物假体器官、机械器官和组织工程器官的市场。在生物假体器官中，我们分别分析了生物假体肾臟和生物假体肝臟。生物假体肾臟进一步细分为基于过滤的系统和混合功能单元，而生物假体肝臟则进一步细分为基于肝细胞的系统和基于支架的单元。机械器官类别进一步细分为透析机、体外膜氧合（ECMO）和心室辅助装置。透析机细分为血液透析及腹膜透析。体外膜氧合（ECMO）分为静脉-静脉ECMO（VA-ECMO）和静脉-静脉ECMO（VV-ECMO）。心室辅助装置分为左心室辅助装置及右心室辅助装置。组织工程分为细胞疗法和支架建构。细胞疗法又分为原代细胞疗法和干细胞疗法。支架建构又分为去细胞支架和功能化支架。

区域监管差异影响着美洲、欧洲、中东、非洲和亚太地区的临床基础设施和生产能力，从而决定了市场进入和扩大策略。

区域趋势对临床试验设计、监管策略、製造地选址和分销模式产生深远影响。在美洲，完善的临床研究基础设施和成熟的报销体系促进了新型医疗设备和生物製药製剂的早期应用。特定细分市场的集中采购也能加速大规模推广。在欧洲、中东和非洲，不同的法规环境和采购系统强调已证实的成本效益和长期疗效，与当地临床中心的伙伴关係模式通常能加速市场准入。亚太地区的特点是临床研究和生产能力快速提升，不断完善的法规结构框架提高了创新再生医学和混合疗法的接受度，以及不断壮大的本土製造商群体增强了区域自主性。

在人工器官开发领域，整合先进的工程技术、细胞生物学专业知识、法规遵循和可扩展的生产能力，是决定竞争优势的关键。

人工器官领域的竞争格局由成熟的医疗设备製造商、生物技术创新者、大学衍生企业和专业合约开发公司组成。主要企业凭藉其在工程、细胞生物学、临床开发和法规遵从方面的综合能力脱颖而出，从而能够将复杂的复合产品从研发阶段推进到临床应用。新创公司通常追求特定的技术优势，例如专有的支架化学、先进的生物列印平台和细胞获取技术，而Start-Ups企业则利用规模、现有的临床关係和分销管道来加速产品推广应用。

对于开发和部署人造器官的公司而言，实际的策略挑战在于专注于平台模组化、强大的供应链，以及产生能够获得报销和广泛应用的证据。

针对行业领导者的具体策略着重于将研发投资与切实可行的部署路径相匹配，建立具有韧性的供应链，并建立支持医保报销和临床认可的循证模型。首先，优先发展能够跨器官和产品类型实现模组化的平台技术。这些平台可以降低边际开发成本，并创造跨适应症的选择。其次，儘早投资于品质系统和生产柔软性。迁移製造地或扩大特定製程规模的能力可以降低关税风险和供应衝击。

为了支持策略决策，我们采用高度透明的混合调查方法，结合相关人员访谈、监管比较、技术成熟度评估和证据三角验证。

本执行摘要的研究采用了混合方法，结合了访谈、文献整合、监管文件分析和技术成熟度评估。访谈对象包括临床医生、采购经理、监管专家和研发主管，检验关键假设并识别临床部署中的操作挑战。文献整合研究涵盖了同行评审期刊、临床试验註册资讯、专利申请和行业指南文件，以阐明技术进步的背景，并识别医疗设备检验和监管政策中的关键转折点。

对技术可行性、临床需求和运作准备进行综合分析，可以确定哪些人工器官​​解决方案将从创新过渡到标准临床应用。

人工器官领域正处于转折点，科学可行性、临床需求和商业性可行性正在融合，这将显着改善器官衰竭患者的治疗。儘管技术和监管方面的挑战仍然存在，但模组化平台开发、有针对性的临床策略和稳健的生产计划相结合，正在为人工器官的广泛应用铺平道路。需要强调的是，必须制定全面的证据策略，超越初步的安全性验证，涵盖长期功能和以患者为中心的疗效，因为保险公司和医疗服务提供者所要求的可验证疗效将决定哪些解决方案能够实现规模化应用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以器官类型分類的人工器官市场

  • 心
  • 肾
  • 肝
  • 肺
  • 胰臟

第九章：人工器官市场：依产品类型划分

  • 生物人工
    • 生物人工肾臟
      • 基于过滤的系统
      • 混合功能单元
    • 生物人工肝臟
      • 基于肝细胞的系统
      • 鹰架底座单元
  • 机械的
    • 透析机
      • 血液透析
      • 腹膜透析
    • 体外膜氧合器
      • VA-ECMO
      • VV-ECMO
    • 心室辅助装置
      • 左心室辅助装置
      • 右心辅助装置
  • 组织工程
    • 细胞疗法
      • 初代细胞疗法
      • 干细胞疗法
    • 基于支架的结构
      • 去细胞支架
      • 功能化支架

第十章：人工器官市场：依技术划分

  • 3D生物列印
    • 挤出式
    • 喷墨法
    • 雷射辅助型
  • 去细胞化
  • 微流体技术
  • 鹰架技术
  • 穿戴式装置

第十一章：人工器官市场：依最终用户划分

  • 门诊部
    • 诊所
    • 日间手术中心
  • 医院
    • 私立医院
    • 公立医院
  • 研究机构
  • 专科诊所

第十二章：人工器官市场：依分销管道划分

  • 直销
  • 销售代理
  • 医院采购
  • 线上平台

第十三章：人工器官市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：人工器官市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：人工器官市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国人工器官市场

第十七章：中国的人造器官市场

第十八章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alt-Bionics, LLC
  • Axiles Bionics
  • Baxter International Inc.
  • Berlin Heart GmbH
  • Beta Bionics, Inc.
  • Bionic India
  • Boston Scientific Corporation
  • Carmat SA
  • COVVI Ltd.
  • Ekso Bionics Holdings, Inc.
  • German Bionic Systems GmbH
  • iWALKFree, Inc.
  • Jarvik Heart, Inc.
  • Medtronic Plc
  • Nipro Corporation
  • Open Bionics Ltd.
  • Pixium Vision SA
  • ReWalk Robotics Ltd.
  • Sonova AG
  • SynCardia Systems, LLC
  • Vivani Medical, Inc.
  • Zimmer Biomet Holdings, Inc.
  • Ossur hf.
Product Code: MRR-2B5802CFEB3A

The Artificial Organs Market was valued at USD 32.95 billion in 2025 and is projected to grow to USD 35.84 billion in 2026, with a CAGR of 9.26%, reaching USD 61.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 32.95 billion
Estimated Year [2026] USD 35.84 billion
Forecast Year [2032] USD 61.28 billion
CAGR (%) 9.26%

An integrative overview of how biological engineering and advanced device platforms are converging to transform treatment options and clinical pathways for organ failure

The development and deployment of artificial organs represent a convergence of biological science, engineering, and clinical practice that is reshaping treatment paradigms for end-stage organ failure. Across diagnostics, temporary support systems, and long-term implantable solutions, technological advances in materials, cellular biology, and manufacturing are expanding therapeutic options and creating new models of care. Clinicians are increasingly able to rely on hybrid approaches that combine mechanical support with biofunctional components to stabilize patients, bridge to transplant, or provide definitive therapy when transplantation is not possible.

At the same time, regulatory frameworks and payer considerations are evolving to accommodate products that blur the lines between devices, biologics, and combination therapies. Investment interest has broadened from niche medtech investors to large strategic players and life sciences funds, reflecting confidence in the scientific pathway and commercial potential. As a result, stakeholders from research institutes to specialty clinics are recalibrating clinical pathways, supply chains, and capital allocation to engage with an emerging ecosystem that demands integrated capabilities in manufacturing, quality systems, and post-market evidence generation.

This executive summary distills the most consequential dynamics affecting innovation, commercialization, and adoption of artificial organs. It frames the competitive landscape by technology, product archetype, end user, and distribution dynamics while highlighting regional and policy drivers that will influence strategic choices over the near to medium term.

How technological convergence regulatory adaptation and strategic partnerships are reshaping product pathways clinical care models and commercialization strategies in artificial organ development

The landscape for artificial organs is undergoing transformative shifts driven by three interlocking trends: technological convergence, clinical pathway redesign, and supply chain resilience. Advances in 3D bioprinting, scaffold engineering, and microfluidic modeling are enabling prototypes that were speculative a decade ago to enter clinical validation. Consequently, product development timelines are shortening for some modalities, and hybrid solutions that couple mechanical support with biological functionality are progressing from preclinical studies into early human use.

Clinical practice is adapting in parallel. Multidisciplinary care teams are establishing new protocols to integrate temporary extracorporeal support, implantable assist devices, and biological adjuncts into treatment sequences. These changes are enhancing patient throughput in ambulatory and hospital settings while also raising the importance of long-term follow-up and registry-driven outcomes measurement. As reimbursement units evolve, payers and providers are increasingly focused on evidence that demonstrates not only survival benefit but also quality-of-life improvements and reductions in downstream resource utilization.

From a commercialization standpoint, strategic partnerships between device firms, contract developers, and specialized contract manufacturers are becoming more prevalent. These partnerships support rapid iteration while ensuring compliance with rigorous quality standards. Meanwhile, capital allocation is shifting toward platform technologies that can be adapted across organ types and product modalities, thereby allowing organizations to amortize development cost across multiple clinical indications. Taken together, these shifts create windows of opportunity for first movers who can integrate scientific rigor with scalable manufacturing and robust post-market evidence generation.

Assessing how changes in United States tariff policy in 2025 are reshaping supply chains procurement strategies and manufacturing localization decisions for artificial organ manufacturers

Recent tariff policy changes in the United States have introduced material implications for supply chains, component sourcing, and pricing strategies among manufacturers and distributors engaged in the artificial organs sector. Tariff adjustments affect imported raw materials and specialized components used in device manufacturing, such as polymers, precision pumps, sensors, and biologics handling equipment, thereby influencing manufacturers' input cost structures and procurement planning. Given the complexity of contemporary artificial organ systems, even incremental increases in the cost of feedstock or subassemblies can create ripple effects across bill-of-material calculations and contractual pricing commitments with health systems.

In response, manufacturers have employed a range of mitigation tactics. Some firms have localized critical manufacturing steps to reduce exposure to cross-border duties, while others have diversified supplier networks to identify lower-cost or tariff-exempt sources. Additionally, organizations are recalibrating inventory strategies to manage cash flow impacts created by increased landed costs and to protect production continuity against tariff-induced volatility. These approaches carry trade-offs: localization enhances control and may reduce tariff exposure but can require significant capital investment and lead time to scale; supplier diversification reduces single-source risk but increases complexity in quality assurance and supplier qualification.

Policy transparency and predictable tariff schedules are essential for long-term investment in high-capital manufacturing infrastructure. Consequently, market participants are engaging more actively with trade advisors, customs experts, and policy stakeholders to anticipate shifts and optimize supply chain configurations. Moving forward, firms that invest early in flexible manufacturing platforms and in-country capabilities will be better positioned to manage tariff risk while preserving their ability to innovate and meet clinical demand.

A detailed segmentation framework linking organ indication product archetype technology platform end user and distribution pathways to guide prioritization of development and commercial investments

Segmentation analysis provides a practical lens for understanding how patient needs, technology choices, and care settings interact to shape product development and commercial strategies. Based on Organ Type, the market is studied across Heart, Kidney, Liver, Lung, and Pancreas, and each organ pathway creates distinct clinical endpoints, device requirements, and regulatory considerations that influence clinical trial design and adoption curve. Based on Product Type, the market is studied across Bioartificial, Mechanical, and Tissue Engineered. Within Bioartificial, the analysis differentiates Bioartificial Kidney and Bioartificial Liver; the Bioartificial Kidney is further studied across Filtration-Based Systems and Hybrid Functional Units, while the Bioartificial Liver is further studied across Hepatocyte-Based Systems and Scaffold-Based Units. The Mechanical category is further studied across Dialysis Machine, Extracorporeal Membrane Oxygenation, and Ventricular Assist Device. The Dialysis Machine division is further studied across Hemodialysis and Peritoneal Dialysis. The Extracorporeal Membrane Oxygenation category is further studied across VA-ECMO and VV-ECMO. The Ventricular Assist Device division is further studied across Left Ventricular Assist Device and Right Ventricular Assist Device. The Tissue Engineered category is further studied across Cell-Based Therapies and Scaffold-Based Constructs. The Cell-Based Therapies area is further studied across Primary Cell Therapies and Stem Cell Therapies. The Scaffold-Based Constructs area is further studied across Decellularized Scaffolds and Functionalized Scaffolds.

Based on Technology, the market is studied across 3D Bioprinting, Decellularization, Microfluidics, Scaffold Technology, and Wearable Devices, and the 3D Bioprinting stream is further studied across Extrusion-Based, Inkjet-Based, and Laser-Assisted approaches. These distinctions matter because device complexity, validation pathways, and manufacturing requirements vary substantially between a filtration-based mechanical unit and a scaffold-based tissue engineered construct. Based on End User, the market is studied across Ambulatory Care Centers, Hospitals, Research Institutes, and Specialty Clinics; the Ambulatory Care Centers segment is further studied across Clinics and Day Surgery Centers, and the Hospitals segment is further studied across Private Hospitals and Public Hospitals. These end-user distinctions influence not only procurement processes but also training requirements and capital expenditure cycles.

Based on Distribution Channel, the market is studied across Direct Sales, Distributors, Hospital Procurement, and Online Platforms, and the channel strategy directly affects pricing, field support investments, and service models. Combining these segmentation dimensions reveals where clinical need, technology readiness, and commercial pathways overlap, thereby helping stakeholders prioritize development portfolios and align investment with the most promising clinical and commercial opportunities.

How regional regulatory nuances clinical infrastructure and manufacturing capabilities across the Americas Europe Middle East & Africa and Asia-Pacific dictate differentiated market entry and scale strategies

Regional dynamics exert a profound influence on clinical trial design, regulatory strategy, manufacturing location decisions, and distribution models. In the Americas, strong clinical research infrastructure and established reimbursement mechanisms facilitate early adoption of novel device and biological solutions, while centralized procurement in certain submarkets can accelerate scaled deployments. Europe Middle East & Africa presents heterogenous regulatory climates and procurement systems that reward demonstrated cost-effectiveness and long-term outcomes, and partnership models with local clinical centers often expedite market entry. Asia-Pacific is characterized by rapid capacity building in both clinical research and manufacturing, evolving regulatory frameworks that are increasingly receptive to innovative regenerative and hybrid therapies, and a growing base of domestic manufacturers that are enhancing regional self-sufficiency.

Each region also presents particular considerations for evidence generation and commercialization. In the Americas, payers demand robust comparative effectiveness data and real-world evidence to support reimbursement pathways. In Europe Middle East & Africa, harmonization initiatives and regional regulatory cooperation create opportunities but also require nuanced local strategies. In Asia-Pacific, rapid patient volumes and increasing healthcare spending create compelling use cases for scalable artificial organ solutions, but successful market entry often requires local partnerships and adaptation to country-specific clinical practices.

Taken together, regional insights underscore the importance of tailoring regulatory, clinical, and commercial plans to local realities. Firms that align trial design, manufacturing footprint, and distribution approach to the specific features of the Americas, Europe Middle East & Africa, and Asia-Pacific will find clearer paths to adoption and sustainable scale.

Why integrated capabilities spanning advanced engineering cellular expertise regulatory mastery and scalable manufacturing are decisive factors shaping competitive advantage in artificial organ development

Competitive dynamics in the artificial organs domain are defined by a mix of established medical device manufacturers, biotech innovators, academic spinouts, and specialized contract developers. Leading organizations differentiate through integrated capabilities in engineering, cellular biology, clinical development, and regulatory affairs, enabling them to move complex combination products through development and into clinical practice. Startups frequently pursue focused technical advantages-such as proprietary scaffold chemistry, advanced bioprinting platforms, or cell sourcing technologies-while established firms leverage scale, existing clinical relationships, and distribution channels to accelerate adoption.

Collaboration models are central to competitive positioning. Companies increasingly form strategic alliances to pool expertise and share development risk, combining clinical access from academic partners with manufacturing and commercialization strengths from industrial partners. In addition, selective acquisitions and licensing agreements remain common mechanisms to fill capability gaps quickly, particularly where firms seek to integrate biological components into mechanical platforms. Manufacturing capability and regulatory know-how are differentiators; companies that secure reliable contract manufacturing partnerships and robust quality systems can shorten time-to-clinic and reduce regulatory friction.

Market leaders also invest in post-market surveillance and outcomes registries to generate longitudinal evidence and to support value-based contracting. Patient-centric design, clinician training programs, and scalable service models further separate organizations that achieve durable adoption from those that face cyclical uptake. Overall, competitive advantage accrues to organizations that can align deep technical know-how with clinical validation, manufacturing scale-up, and channel execution.

Practical strategic imperatives for developers and deployers of artificial organs focused on platform modularity resilient supply chains and evidence generation that enables reimbursement and adoption

Actionable strategies for industry leaders center on aligning R&D investments with realistic adoption pathways, building resilient supply chains, and establishing evidence generation models that support reimbursement and clinical acceptance. First, prioritize platform technologies that offer modularity across organ types and product categories; such platforms reduce marginal development costs and create optionality across indications. Second, invest in quality systems and manufacturing flexibility early, as the ability to shift production between sites or scale specific process steps will mitigate tariff exposure and supply shocks.

Third, develop a staged evidence strategy that moves from rigorously designed early feasibility studies to pragmatic trials and registry-based evidence that captures long-term patient outcomes and health economics. This phased approach supports iterative regulatory submissions and payer engagement while controlling clinical development risk. Fourth, form strategic partnerships that complement internal capabilities; for example, collaborations with specialized CMOs, academic centers, or therapeutic-area experts can accelerate clinical access and reduce time-to-market. Finally, embed clinician training and post-sale support into commercial models to ensure safe use and to drive early demonstrable outcomes that influence procurement decisions.

Taken together, these recommendations emphasize a balanced approach that integrates technical ambition with operational readiness and payer engagement. Leaders who execute on these priorities will increase the probability that their solutions move beyond pilot programs to become standard components of organ failure care pathways.

A transparent mixed methods research approach combining stakeholder interviews regulatory comparison technology readiness assessment and evidence triangulation to support strategic decision making

The research underpinning this executive summary applied a mixed-methods approach combining primary interviews, secondary literature synthesis, regulatory document analysis, and technology readiness assessment. Primary research engaged clinicians, procurement leaders, regulatory experts, and R&D executives to validate key assumptions and to surface operational challenges in clinical adoption. Secondary research encompassed peer-reviewed journals, clinical trial registries, patent filings, and industry guidance documents to contextualize technological progress and to identify inflection points in device validation and regulatory policy.

To assess technology readiness, the study mapped product archetypes against clinical validation stages and manufacturing complexity, identifying where additional biocompatibility testing, scale-up work, or long-term durability data would be required. Regulatory pathways were compared across major jurisdictions to highlight differences in classification, premarket evidence expectations, and post-market obligations. The research team triangulated qualitative insights from interviews with objective indicators, such as the volume of clinical activity in relevant specialties and the trajectory of published preclinical work, to ensure robustness.

Limitations are acknowledged: evolving regulatory decisions, emergent clinical data, and shifting trade policies can alter the practical implications for specific products. Nevertheless, the methodology emphasizes transparency and repeatable criteria, enabling readers to understand the evidence basis for strategic conclusions and to apply the frameworks to their own portfolios.

Synthesis of technological promise clinical imperatives and operational readiness that determines which artificial organ solutions will transition from innovation to standard clinical use

The artificial organs field is at an inflection point in which scientific feasibility, clinical demand, and commercial capability are converging to enable meaningful improvements in care for patients with organ failure. While technical and regulatory hurdles remain, the combination of modular platform development, targeted clinical strategies, and robust manufacturing planning creates realistic pathways to broader adoption. Payer and provider expectations for demonstrable outcomes will shape which solutions scale, underscoring the necessity of comprehensive evidence strategies that extend beyond initial safety demonstrations to encompass long-term function and patient-centered outcomes.

Looking ahead, organizations that align their product portfolios to clear clinical needs, invest in flexible and quality-driven manufacturing, and proactively manage policy and trade risk will be best positioned to capture value. Collaboration across industry, academia, and clinical systems will accelerate translation, but commercial success will ultimately favor entities that can integrate scientific innovation with operational excellence and credible, longitudinal evidence of benefit. In sum, the near-term horizon offers substantive opportunities for those who execute a disciplined approach to technology maturation, clinical validation, and market access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Organs Market, by Organ Type

  • 8.1. Heart
  • 8.2. Kidney
  • 8.3. Liver
  • 8.4. Lung
  • 8.5. Pancreas

9. Artificial Organs Market, by Product Type

  • 9.1. Bioartificial
    • 9.1.1. Bioartificial Kidney
      • 9.1.1.1. Filtration-Based Systems
      • 9.1.1.2. Hybrid Functional Units
    • 9.1.2. Bioartificial Liver
      • 9.1.2.1. Hepatocyte-Based Systems
      • 9.1.2.2. Scaffold-Based Units
  • 9.2. Mechanical
    • 9.2.1. Dialysis Machine
      • 9.2.1.1. Hemodialysis
      • 9.2.1.2. Peritoneal Dialysis
    • 9.2.2. Extracorporeal Membrane Oxygenation
      • 9.2.2.1. VA-ECMO
      • 9.2.2.2. VV-ECMO
    • 9.2.3. Ventricular Assist Device
      • 9.2.3.1. Left Ventricular Assist Device
      • 9.2.3.2. Right Ventricular Assist Device
  • 9.3. Tissue Engineered
    • 9.3.1. Cell-Based Therapies
      • 9.3.1.1. Primary Cell Therapies
      • 9.3.1.2. Stem Cell Therapies
    • 9.3.2. Scaffold-Based Constructs
      • 9.3.2.1. Decellularized Scaffolds
      • 9.3.2.2. Functionalized Scaffolds

10. Artificial Organs Market, by Technology

  • 10.1. 3D Bioprinting
    • 10.1.1. Extrusion-Based
    • 10.1.2. Inkjet-Based
    • 10.1.3. Laser-Assisted
  • 10.2. Decellularization
  • 10.3. Microfluidics
  • 10.4. Scaffold Technology
  • 10.5. Wearable Devices

11. Artificial Organs Market, by End User

  • 11.1. Ambulatory Care Centers
    • 11.1.1. Clinics
    • 11.1.2. Day Surgery Centers
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Artificial Organs Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Hospital Procurement
  • 12.4. Online Platforms

13. Artificial Organs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Organs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Organs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Organs Market

17. China Artificial Organs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alt-Bionics, LLC
  • 18.6. Axiles Bionics
  • 18.7. Baxter International Inc.
  • 18.8. Berlin Heart GmbH
  • 18.9. Beta Bionics, Inc.
  • 18.10. Bionic India
  • 18.11. Boston Scientific Corporation
  • 18.12. Carmat SA
  • 18.13. COVVI Ltd.
  • 18.14. Ekso Bionics Holdings, Inc.
  • 18.15. German Bionic Systems GmbH
  • 18.16. iWALKFree, Inc.
  • 18.17. Jarvik Heart, Inc.
  • 18.18. Medtronic Plc
  • 18.19. Nipro Corporation
  • 18.20. Open Bionics Ltd.
  • 18.21. Pixium Vision SA
  • 18.22. ReWalk Robotics Ltd.
  • 18.23. Sonova AG
  • 18.24. SynCardia Systems, LLC
  • 18.25. Vivani Medical, Inc.
  • 18.26. Zimmer Biomet Holdings, Inc.
  • 18.27. Ossur hf.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL ORGANS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL ORGANS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL ORGANS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL ORGANS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY FILTRATION-BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY FILTRATION-BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY FILTRATION-BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HYBRID FUNCTIONAL UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HYBRID FUNCTIONAL UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HYBRID FUNCTIONAL UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEPATOCYTE-BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEPATOCYTE-BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEPATOCYTE-BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VA-ECMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VA-ECMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VA-ECMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VV-ECMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VV-ECMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VV-ECMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRIMARY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRIMARY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRIMARY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DECELLULARIZED SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DECELLULARIZED SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DECELLULARIZED SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY FUNCTIONALIZED SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY FUNCTIONALIZED SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY FUNCTIONALIZED SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRUSION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRUSION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY EXTRUSION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY INKJET-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY INKJET-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY INKJET-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LASER-ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LASER-ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY LASER-ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DECELLULARIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DECELLULARIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DECELLULARIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DAY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DAY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DAY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY BIOARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY DIALYSIS MACHINE, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY TISSUE ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY CELL-BASED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY SCAFFOLD-BASED CONSTRUCTS, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY 3D BIOPRINTING, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC ARTIFICIAL ORGANS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. GLOBAL ARTIFICIAL ORGANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN ARTIFICIAL ORGANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION